Instability of the mitochondrial alanyl-tRNA synthetase underlies fatal infantile-onset cardiomyopathy.
Alanine-tRNA Ligase
/ genetics
Cardiomyopathies
/ enzymology
Diseases in Twins
/ genetics
Enzyme Stability
Fibroblasts
/ metabolism
Genes, Recessive
Humans
Infant
Lactic Acid
Male
Mitochondria
/ metabolism
Mitochondrial Proteins
/ biosynthesis
Muscle, Skeletal
/ metabolism
Myocardium
/ metabolism
Pedigree
Respiratory Insufficiency
/ enzymology
Journal
Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
12
06
2018
accepted:
07
08
2018
pubmed:
5
10
2018
medline:
5
6
2019
entrez:
5
10
2018
Statut:
ppublish
Résumé
Recessively inherited variants in AARS2 (NM_020745.2) encoding mitochondrial alanyl-tRNA synthetase (mt-AlaRS) were first described in patients presenting with fatal infantile cardiomyopathy and multiple oxidative phosphorylation defects. To date, all described patients with AARS2-related fatal infantile cardiomyopathy are united by either a homozygous or compound heterozygous c.1774C>T (p.Arg592Trp) missense founder mutation that is absent in patients with other AARS2-related phenotypes. We describe the clinical, biochemical and molecular investigations of two unrelated boys presenting with fatal infantile cardiomyopathy, lactic acidosis and respiratory failure. Oxidative histochemistry showed cytochrome c oxidase-deficient fibres in skeletal and cardiac muscle. Biochemical studies showed markedly decreased activities of mitochondrial respiratory chain complexes I and IV with a mild decrease of complex III activity in skeletal and cardiac muscle. Using next-generation sequencing, we identified a c.1738C>T (p.Arg580Trp) AARS2 variant shared by both patients that was in trans with a loss-of-function heterozygous AARS2 variant; a c.1008dupT (p.Asp337*) nonsense variant or an intragenic deletion encompassing AARS2 exons 5-7. Interestingly, our patients did not harbour the p.Arg592Trp AARS2 founder mutation. In silico modelling of the p.Arg580Trp substitution suggested a deleterious impact on protein stability and folding. We confirmed markedly decreased mt-AlaRS protein levels in patient fibroblasts, skeletal and cardiac muscle, although mitochondrial protein synthesis defects were confined to skeletal and cardiac muscle. In vitro data showed that the p.Arg580Trp variant had a minimal effect on activation, aminoacylation or misaminoacylation activities relative to wild-type mt-AlaRS, demonstrating that instability of mt-AlaRS is the biological mechanism underlying the fatal cardiomyopathy phenotype in our patients.
Identifiants
pubmed: 30285085
pii: 5114638
doi: 10.1093/hmg/ddy294
pmc: PMC6321959
doi:
Substances chimiques
Mitochondrial Proteins
0
Lactic Acid
33X04XA5AT
Alanine-tRNA Ligase
EC 6.1.1.7
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-268Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0800674
Pays : United Kingdom
Références
Nat Genet. 2007 Apr;39(4):534-9
pubmed: 17384640
Hum Mol Genet. 2017 Oct 1;26(R2):R114-R127
pubmed: 28633377
JAMA. 2014 Jul 2;312(1):68-77
pubmed: 25058219
JIMD Rep. 2017;33:61-68
pubmed: 27571996
Hum Mutat. 2014 Nov;35(11):1285-9
pubmed: 25130867
Hum Mutat. 2017 Jun;38(6):621-636
pubmed: 28236339
Sci Transl Med. 2012 Oct 3;4(154):154ra135
pubmed: 23035047
Mol Genet Genomic Med. 2015 Jan;3(1):59-68
pubmed: 25629079
Neurology. 2014 Jun 10;82(23):2063-71
pubmed: 24808023
Nucleic Acids Res. 2013 Nov;41(21):9825-38
pubmed: 23969415
Nucleic Acids Res. 2018 Jan 25;46(2):849-860
pubmed: 29228266
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16209-14
pubmed: 19805282
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
J Hum Genet. 2017 Feb;62(2):329-333
pubmed: 27734837
Am J Hum Genet. 2011 May 13;88(5):635-42
pubmed: 21549344
Sci Transl Med. 2014 Dec 3;6(265):265ra168
pubmed: 25473036
J Biol Chem. 2016 Mar 18;291(12):6507-20
pubmed: 26811336
Nature. 2014 Jun 26;510(7506):507-11
pubmed: 24919148
Methods Cell Biol. 2007;80:93-119
pubmed: 17445690
Int J Cell Biol. 2014;2014:787956
pubmed: 24639874
J Perinat Med. 2018 Nov 27;46(9):968-974
pubmed: 28822227
Neuromuscul Disord. 2004 Apr;14(4):237-45
pubmed: 15019701
Neurol Genet. 2017 Feb 15;3(2):e135
pubmed: 28243630
J Hum Genet. 2016 Oct;61(10):899-902
pubmed: 27251004
Nature. 2009 Dec 10;462(7274):808-12
pubmed: 20010690
Ophthalmic Genet. 2018 Jan-Feb;39(1):99-102
pubmed: 28820624
Brain. 2003 Aug;126(Pt 8):1905-12
pubmed: 12805096
J Med Genet. 2006 Apr;43(4):295-305
pubmed: 16014699
Mol Genet Metab. 2013 Apr;108(4):206-11
pubmed: 23433712
Annu Rev Genomics Hum Genet. 2017 Aug 31;18:257-275
pubmed: 28415858
Nature. 2008 Jan 3;451(7174):90-3
pubmed: 18172502
Am J Hum Genet. 2007 Oct;81(4):857-62
pubmed: 17847012
Cell Tissue Res. 2017 Jan;367(1):5-20
pubmed: 27411691
Front Genet. 2015 Feb 06;6:21
pubmed: 25705216
Sci Transl Med. 2012 Jan 25;4(118):118ra10
pubmed: 22277967
JAMA Neurol. 2016 Dec 1;73(12):1433-1439
pubmed: 27749956
Cardiol Young. 2017 Jul;27(5):936-944
pubmed: 27839525
PLoS Biol. 2012;10(3):e1001288
pubmed: 22448145
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Hum Mutat. 2014 Aug;35(8):983-9
pubmed: 24827421
Neurology. 2014 Dec 2;83(23):2183-7
pubmed: 25361775
Trends Mol Med. 2017 Aug;23(8):693-708
pubmed: 28716624
Eur J Hum Genet. 2018 Apr;26(4):537-551
pubmed: 29440775
Hum Mol Genet. 2012 Oct 15;21(20):4521-9
pubmed: 22833457